Rigel Pharmaceuticals Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
174
- Stock Symbol
-
RIGL
- Investments
-
1
- Share Price
-
$44.46
- (As of Friday Closing)
Rigel Pharmaceuticals General Information
Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
Contact Information
Website
www.rigel.comCorporate Office
- 611 Gateway Boulevard
- Suite 900
- South San Francisco, CA 94080
- United States
Corporate Office
- 611 Gateway Boulevard
- Suite 900
- South San Francisco, CA 94080
- United States
Rigel Pharmaceuticals Stock Performance
As of 13-Nov-2026, Rigel Pharmaceuticals’s stock price is $44.46. Its current market cap is $837M with 18.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $44.46 | $45.69 | $24.95 - $52.60 | $837M | 18.8M | 258K | $16.83 |
Rigel Pharmaceuticals Financials Summary
As of 30-Sep-2026, Rigel Pharmaceuticals has a trailing 12-month revenue of $288M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 844,056 | 701,159 | 295,399 | 251,283 |
| Revenue | 288,213 | 294,282 | 179,278 | 116,882 |
| EBITDA | 79,574 | 127,881 | 26,420 | (19,253) |
| Net Income | 307,194 | 367,024 | 17,485 | (25,091) |
| Total Assets | 523,877 | 513,594 | 163,976 | 117,225 |
| Total Debt | 7,792 | 53,303 | 59,965 | 60,579 |
Rigel Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Rigel Pharmaceuticals Comparisons
Industry
Financing
Details
Rigel Pharmaceuticals Competitors (48)
One of Rigel Pharmaceuticals’s 48 competitors is Dicerna Pharmaceuticals, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | Formerly VC-backed | Lexington, MA | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| Gyre Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA | ||||
| United Therapeutics | Formerly VC-backed | Silver Spring, MD |
Rigel Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rigel Pharmaceuticals Patents
Rigel Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026122127-A1 | Irak inhibitor for the treatment of a myelodisplastic syndrome | Pending | 06-Dec-2024 | ||
| US-20260158048-A1 | Methods of treatment | Pending | 06-Dec-2024 | ||
| US-20260157970-A1 | Pharmaceutical compositions | Pending | 06-Dec-2024 | ||
| WO-2026122888-A1 | Pharmaceutical compositions comprising 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol -4-yl)carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate or its salts | Pending | 06-Dec-2024 | ||
| WO-2026122925-A1 | Solid forms of 1-(4-(4-((3-(3,6-difluoropyridin-2-yl)-1-((1r,4r)-4-ethoxycyclohexyl)-1h-pyrazol-4-yl) carbamoyl)thiazol-2-yl)-1h-pyrazol-1-yl)ethyl phosphate and salts thereof, and their pharmaceutical compositions and uses | Pending | 06-Dec-2024 | C07F9/65583 |
Rigel Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Rigel Pharmaceuticals Investments (1)
Rigel Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with Blueprint Medicines (US Rights of Gavreto) for . The deal was made on 22-Feb-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Blueprint Medicines (US Rights of Gavreto) | 22-Feb-2024 | Corporate Asset Purchase | Buildings and Property |
Rigel Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
30.39 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Rigel Pharmaceuticals FAQs
-
When was Rigel Pharmaceuticals founded?
Rigel Pharmaceuticals was founded in 1996.
-
Where is Rigel Pharmaceuticals headquartered?
Rigel Pharmaceuticals is headquartered in South San Francisco, CA.
-
What is the size of Rigel Pharmaceuticals?
Rigel Pharmaceuticals has 174 total employees.
-
What industry is Rigel Pharmaceuticals in?
Rigel Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Rigel Pharmaceuticals a private or public company?
Rigel Pharmaceuticals is a Public company.
-
What is Rigel Pharmaceuticals’s stock symbol?
The ticker symbol for Rigel Pharmaceuticals is RIGL.
-
What is the current stock price of Rigel Pharmaceuticals?
As of 13-Nov-2026 the stock price of Rigel Pharmaceuticals is $44.46.
-
What is the current market cap of Rigel Pharmaceuticals?
The current market capitalization of Rigel Pharmaceuticals is $837M.
-
What is Rigel Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Rigel Pharmaceuticals is $288M.
-
Who are Rigel Pharmaceuticals’s competitors?
Dicerna Pharmaceuticals, Regeneron Pharmaceuticals, Gyre Therapeutics, BioMarin Pharmaceutical, and United Therapeutics are some of the 48 competitors of Rigel Pharmaceuticals.
-
What is Rigel Pharmaceuticals’s annual earnings per share (EPS)?
Rigel Pharmaceuticals’s EPS for 12 months was $16.83.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
